Arcutis Canada, Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has approved PrZORYVE® (roflumilast foam ...

Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus will ...